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Abstract
Background: Routine rapid testing for Bovine Spongiform Encephalopathy (BSE) has highlighted some problems
with BSE rapid test performance, the most significant being the number of initially reactive samples and the false
positive results on autolyzed tissue. This point is important for BSE active surveillance in risk populations, because
tissue autolysis is often unavoidable in routine cases. A robust test suitable for use on field material is therefore
needed. To date, very limited information regarding the effect of autolysis on the robustness of rapid tests has
been documented; therefore, the National Reference Centre for Animal Encephalopathies (CEA) rapid test
laboratory selected 450 autolyzed and negative brain stem samples from fallen stock bovines older than 24
months to assess the specificity of four tests approved for BSE active surveillance: Biorad TeSeE, Enfer TSE version
2.0, Prionics® Check LIA, and IDEXX Herd Check BSE Antigen Kit EIA. The samples were graded according to the
degree of autolysis and then dissected into five portions, four of which randomly assigned to processing by rapid
tests and one to be available for confirmatory Western blot analysis.
Findings: The specificity of the four systems was 100% for all three grades of autolysis, while the percentage of
initially reactive results was 0.00 (95%CI 0.00-0.82), 0.22 (95%CI 0.006-1.23), 0.44 (95%CI 0.05-1.60), and 0.89 (95%CI
0.24-2.26) for the Biorad TeSeE, the Prionics® Check LIA, the IDEXX Herd Check BSE and the Enfer TSE tests,
respectively. No association with the degree of autolysis could be drawn.
Conclusions: The present study demonstrates that the four rapid tests can be considered well-running diagnostic
tools regardless of tissue quality; nevertheless, the number of initial reactive samples reported for some systems
must not be underestimated in routine testing.
Furthermore the compliance with the reported performance can be guaranteed only when an ongoing high care-
ful batch quality control system is in place.
Background
Bovine spongiform encephalopathy (BSE), a fatal infec-
tious neurodegenerative disease of cattle, is characterized
by the concentration of an anomalous isoform of the nat-
ural prion protein (PrP
c), denominated PrP
res, in the cen-
tral nervous system (CNS) [1,2]. PrP
res differs from PrP
c
in its high insolubility and partial protease resistance:
these characteristics are exploited by the majority of the
methods currently used for BSE diagnosis. Evidence for
the origin of variant Creutzfeldt-Jakob Disease (vCJD)
from BSE [3,4] led the European Commission (EC) to
strengthen control programs, introducing active
surveillance by means of rapid tests to monitor the rumi-
nant infection [5]. Since 1999 the EC has assessed 19
rapid tests, 9 of which were approved for survey includ-
ing a new version of the Enfer TSE test for BSE diagnosis
[6].
In 1999 the EC carried out the first scientific evalua-
tion of four new rapid post mortem BSE tests in which
diagnostic accuracy and analytic sensitivity on brain tis-
sue from clinically affected bovines was assessed [7].
Subsequent EU validation exercises extended assessment
parameters to include test robustness on autolyzed
material as a fundamental criterion, simulating routine
field diagnosis [8-10].
Active surveillance samples come primarily from
slaughtered animals; for this target category the caudal
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death and sent to the laboratory. But a fairly high per-
centage of samples (13.5% in 2007 in EU Member States
[11]) come from fallen stock cattle; in Italy, some 90%
of samples arrive at the laboratory in condition of auto-
lysis, owing to the time between the animal’s death and
collectionof the sample.
Previous studies investigated the effect of autolytic
changes on the detection of Scrapie-associated fibrils
(SAF) [12,13] and then on PrP
res immunodetection by
immunoblotting and immunohistochemistry [14-17].
The ability of some rapid test systems to correctly clas-
sify BSE autolyzed positive samples was also ascertained
[18]. The outcome of those studies was an undiminished
sensitivity for PrP
res detection for all diagnostic methods
evaluated, even when applied to severely autolyzed
tissues.
To date, there is a little reliable information [19] about
the effect autolysis can have on rapid test performance
for large-scale throughput samples in terms of number
of initially reactive samples and false positive results. To
fill this gap, we wanted to determine whether natural
autolysis affected the performance of four rapid tests
commonly used in the EU for mandatory surveillance of
BSE (Prionics® Check-LIA Test, Enfer TSE Kit version
2.0, Bio-Rad TeSeE Test, IDEXX HerdChek BSE Anti-
gen Test Kit EIA) on negative and autolyzed field
samples.
Methods
Samples
A total of 450 autolyzed bovine brain stem samples
(medulla oblongata at the level of the obex) from fallen
stock animals older than 24 months, sent to the Rapid
Test Laboratory of the National Reference Centre for
TSE (CEA - National Reference Laboratory [NRL]) for
BSE monitoring, were collected from June to September
2008 and assigned a progressive number.
Protocol
Samples coming to the laboratory were graded accord-
ing to the degree of autolysis as follows:
■ Grade 1: reduced consistence, obex easily recog-
nizable, absence of abnormal colours;
■ Grade 2: reduced consistence, obex not always
recognizable, presence of abnormal colours;
■ Grade 3: liquid state, obex not recognizable, pre-
sence of abnormal colours.
Up to 150 samples were collected for each grade of
autolysis.
Three grams of recognizable obex tissue were dis-
sected and carefully minced. Approximately 0.6 g of
tissue were randomly assigned to each rapid test:
■ Prionics® Check-LIA Test is a microplate-based
immunoassay (ELISA) that uses monoclonal antibo-
dies to detect proteinase K resistant PrP
res (Test A);
■ Enfer TSE Kit version 2.0 automated sample pre-
paration is a chemiluminescent ELISA test involving
an extraction procedure and an ELISA technique that
uses an enhanced chemiluminescent reagent (Test B);
■ Bio-Rad TeSeE Test uses a sandwich immunoassay
technique to detect PrP
res following denaturation
and concentration steps (Test C);
■ IDEXX HerdChek BSE Antigen Test Kit EIA is an
immunoassay that uses a chemical polymer for selec-
tive PrP
res capture and a monoclonal detection anti-
body directed against the conserved regions of the
PrP molecule (Test D);.
The fifth aliquot was stored to be available for confir-
matory Western blot assay in case of positive results to
the rapid tests.
For completely autolyzed samples in which the obex
region was not identifiable, the aliquot was taken from
the same tissue area.
The samples were analyzed according to CEA stan-
dard operating protocols based on the test manufac-
turer’s instructions.
Statistics
Percentage of initially reactive samples and specificity
with relative confidence limits at 95% was calculated
using STATA [20] software.
Ethical approval
The samples were collected according to OIE Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals
2008 [21] standard operating protocols in the frame of
Regulation (EC) No 999/2001 [5] dispositions.
Results and discussion
Table 1 reports the number and the percentage of initi-
ally reactive samples by grade of autolysis, as a whole,
and the specificity. Differences among classes of autoly-
sis did not result in statistically significant.
In rapid test validation studies, the objective of field
trials is to demonstrate that the performance of a new
diagnostic system is not inferior to those already
approved for active surveillance. For this purpose, the
diagnostic sensitivity and specificity of a new rapid test
and its robustness are evaluated in field trials carried
out by national reference laboratories (NRL) which run
ah i g hv o l u m eo fs a m p l e so fheterogeneous quality in
parallel with the test in use. All diagnostic tests produce
false positives and false negatives, but the best keep
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recent BSE scenario, in which the epidemic is reported
on the decline in most countries, with only two cases
detected in Italy in 2009, the specificity of the systems
in use is crucial: false reports of new cases unnecessarily
alarm public opinion and even a few false positives can
greatly overstep the true positives a test will detect [7].
Field trials provide test manufacturers with a better
opportunity to acquire practical experience and to
develop the user manual final version. That said, the
real robustness of a test emerges only when it is applied
during routine testing, in different climatic conditions
and on poor quality samples. For this purpose, we tested
only naturally autolyzed samples as documented by pre-
vious studies (Wear et al., 2005) to better mimic routine
field conditions.
According to Italian NRL data, some laboratories reg-
ularly obtain a large number of initially reactive results
from poor-quality samples. This is why verifying the
robustness of rapid tests on autolyzed samples becomes
relevant for BSE surveillance and also for correcting
potential technical problems.
The meaning of surveillance measures could be
affected if rapid test performance is influenced by the
autolysis state per se or because of the loss of neuro-
anatomy of the target area. In this connection, previous
studies [15,16] reported that while correct sampling is
important, tissue quality appears to be a minor factor
influencing false results of a test.
Here we show that all four rapid tests displayed 100%
specificity even in the severely autolyzed samples. How-
ever, differences in test performance on initially reactive
samples were noted, with test C resulting the best-per-
forming system. For the other three tests, a direct link
between the number of initially reactive routes and the
degree of autolysis could not be highlighted either when
initially reactives were taken as a whole or related to a
specific test.
The test A underwent the field trial in 2002, but no
initial reactivity on poor-quality samples was reported.
Our results on this test are in accordance with those
obtained in that frame, while a recent paper from Carra
et all [19] on the evaluation of test A in routine moni-
toring activity reports a high prevalence of false positive
results and frequencies of retested samples on fresh
matrix and, with a higher percentage, on poor quality
tissues. These data could be referred both to individual
batch issues and/or local technical matters.
Nevertheless, it’s worth to be considered that in the
EFSA Scientific Opinion on Analytical sensitivity of
approved TSE rapid tests of 2009 [22] a striking rate of
initial reactive results (100%) achieved on reference nega-
tive tissue samples prepared both according to the manu-
facturer protocol, both with the Central Reference
Laboratory (CRL) for TSE of Weybridge protocol (water:
tissue 50:50), is reported for test A. No repeat testing was
done on initial reactives in the context of this TSE analyti-
cal sensitivity study. Therefore, analytical sensitivity of test
A has been recently re-assessed by CRL for TSEs [23] on
different sets of reference positive and control negative
dilutions prepared according to the manufacturer protocol
without having initial reactive results on negative samples.
Nevertheless the causes of previous initial reactives remain
unidentified. Such situations could highlight a major pro-
blem in the quality control system put in place by the
manufacturer, causing a failure in the performances of sin-
gle batches released for routine activity, independently
from the condition of sample under investigation. As a
matter of fact test A is the only one among the approved
BSE rapid test still not undergoing the official batch test-
ing system, in place since 2008 under the responsibility of
NRLs [24] before the admittance within the EU market.
No initially reactive samples for either the tests B and D
were shown in 2005 field trial. Our results regarding initial
reactive samples by these tests as a whole can be com-
pared to those obtained in EU field trial. The high number
of autolyzed samples tested in this study can partially
explain the apparent differences from the EU evaluation
data, in which the number of autolytic samples tested was
limited (200). This means that, during the EU field trials,
Table 1 Number and percentage of initially reactive samples and specificity
Test Grade 1 Grade 2 Grade 3 Total Specificity
N% N% N% % %
BIORAD TeSeE 0 0.00% 0 0.00% 0 0.00% 0.00% 100%
(95% CI 0.00-2.43)* (95% CI 0.00-2.43)* (95% CI 0.00-2.43)* (95% CI 0.00-0.82) (95% CI 99.18-100)*
ENFER TSE 2 1.33% 1 0.67% 1 0.67% 0.89% 100%
version 2.0 (95% CI 0.16%-4.73) (95% CI 0.02-3.66) (95% CI 0.02-3.66) (95% CI 0.24-2.26) (95% CI 99.18-100)*
Prionics Check LIA 1 0.67% 0 0.00% 0 0.00% 0.22% 100%
(95% CI 0.02-3.66) (95% CI 0.00-2.43)* (95% CI 0.00-2.43)* (95% CI 0.006-1.23) (95% CI 99.18-100)*
IDEXX HerdChek BSE 0 0.00% 0 0.00% 2 1.33% 0.44% 100%
(95% CI 0.00-2.43)* (95% CI 0.00-2.43)* (95% CI 0.16-4.73) (95% CI 0.05-1.60) (95% CI 99.18-100)*
(*) one-sided, 97.5% confidence interval
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initially reactive samples relative to 200 poor-quality sam-
ples tested equals 0% - 1.83%. The percentage of initially
reactive samples in a worst-case scenario of our study
would be 0.89% (4/450 for test D), which is compatible
with the 95% CI of the EU field trial. Furthermore, as
already reported for test A, local technical issues related to
temperature and humidity can not be ignored. Finally, test
C was evaluated as “CEA” test in 1999, but no evaluation
of robustness was provided.
Conclusions
Initially reactive samples need to be retested, as
expected with all test procedures, which leads to
increased laboratory workload. Furthermore, samples
producing false positive results at retesting can create
false alarms and require time-consuming confirmatory
testing. This, in turn, triggers a cascade of public health
measures, including herd quarantine, animal transporta-
tion and slaughter prohibition and bans on commerciali-
zation of milk and by-products until the diagnostic
result is confirmed by the NRL. In the meantime, an
economically wasteful scare begins to spread across the
market. To avert such situations, the screening purpose
of rapid tests dictates that they perform equally well on
autolyzed and good-quality samples alike.
In our study, the poor-quality tissues were still adequate
for testing, highlighting that the robustness of the techni-
ques are not compromised under adverse conditions of
temperature and time between slaughter and testing.
Nonetheless, the problem of initially reactive samples with
regard to some diagnostic systems, must be strategically
considered in laboratories with large workloads.
Other, it should be looked on that unresolved pro-
blems related to the quality control system applied dur-
ing the manufacture of new test batches can severely
affect the performances of rapid tests.
Appendix
Sources and manufacturers
A. Prionics® Check LIA Test, Prionics AG, Wagis-
trasse 27a, CH-8952 Schlieren-Zurich, Switzerland.
B. Enfer TSE test, Enfer Scientific Limited Unit T,
M7 Business Park Newhall, Naas, Co. Kildare,
Ireland
C. Bio-Rad TeSeE, Bio-Rad, 3, Boulevard Raymond
Poincaré, F-92430 Marnes la Coquette, France.
D. IDEXX Herd Check BSE Antigen Kit EIA, Idexx
Laboratories Inc., Westbrook, ME, U.S.
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